Francesco Leone - Concepedia

Author

Francesco Leone

Also Known As

F Leone, F. Leone, Filippo Leone, Francesco Leone, Francesco P. Leone, Francesco Paolo G Leone, Francesco Paolo Giuseppe Leone, Francesco Paolo Leone, Fronzoni Leone, Leone, F.

273

Publications

6.2K

Citations

H-Index

Concepts

All Affiliations

Candiolo Cancer Institute Istituti di Ricovero e Cura a Carattere Scientifico University of Turin Istituto Oncologico Veneto University of Milan

About

Francesco Leone is an author at Candiolo Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	35	3.2K
2	Health Sciences	4	4	223
3	Engineering	3	3	105
4	Social Sciences	1	1	28
5	Behavioral Sciences	1	1	28

Francesco Leone

Publications

5.4K

Citations

H-Index

Page 1

	Year	Citations
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino, The Lancet Oncology OncologyMedicinePathologyColorectal CancerDual-targeted Therapy	2016	984
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study Emanuele Valtorta, Cosimo Martino, Andrea Sartore‐Bianchi, Modern Pathology Her2 Scoring SystemColorectal SurgeryMedicineGastroenterologyColorectal Cancer	2015	309
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer Massimo Aglietta, Carlo Barone, M. B. Sawyer, Annals of Oncology Escalation TrialOncologyPancreatic CancerGastrointestinal OncologyMedicine	2014	216
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study Wouter Froyman, C. Landolfo, B. De Cock, The Lancet Oncology 2-Year Interim AnalysisCancer RiskMedicineCancer ManagementOvarian Tumours	2019	182
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial Andrea Sartore‐Bianchi, Sara Lonardi, Cosimo Martino, ESMO Open OncologyColorectal CancerPathologyCancer TreatmentMedicine	2020	175
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas Ymera Pignochino, Ivana Sarotto, Caterina Peraldo‐Neia, BMC Cancer	2010	172
Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma Francesco Leone, Giuliana Cavalloni, Ymera Pignochino, Clinical Cancer Research	2006	169
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer Andrea Sartore‐Bianchi, Alessio Amatu, Luca Porcu, The Oncologist	2019	165
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Cancer Cell MedicineHer2 BlockadeColorectal CancerPathologyIndividual Metastases	2018	157
Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features Valentina Giannini, Simone Mazzetti, Ilaria Bertotto, European Journal of Nuclear Medicine and Molecular Imaging Oncologic ImagingMedical ImagingNeoadjuvant TherapyMedicinePet-mri	2019	140

Page 1